Form D · Biotechnology
Cupron Inc.
Richmond, VA · CIK 0001482503
Offering snapshot reported Nov 14, 2019 · SEC filing
- Reported sold
- $1.75M Offering amount: $1.75M
- Investors reported
- 24 Form D · investor count
- Minimum accepted
- $1 Reported outside-investor minimum
- First sale
- Sep 3, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 14, 2019 | Initial | $1,750,000 | No comparison | 24 | SEC filing |
| Jan 28, 2010 | Initial | $3,999,632 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-353379
Source: Form D, filed Nov 14, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| William Armfield | Director |
| Sanford M Baklor | Director |
| John Daniel Cudzik | Executive |
| Dafna Gabbay | Director |
| Jeffrey S Gabbay | Executive |
| Sylvain Jakabovics | Director |
| Danny Lustiger | Director, Executive |
| Paul F Rocheleah | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4329 November Avenue
Richmond, VA, 23231
Richmond, VA, 23231